Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norfloxacin for Hepatopulmonary Syndrome
NCT00362752Phase 2Completed
- Sponsor
- Unity Health Toronto
- Start
- Oct 2006
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of norfloxacin in hepatopulmonary syndrome (HPS) (2 arms), sponsored by Unity Health Toronto. Primary endpoint: Alveolar-arterial oxygen gradient at 4 weeks. Started Oct 2006; status: completed.
02
Drugs
norfloxacin
03
Conditions
hepatopulmonary syndrome (HPS)
Beyond the preview
Go deeper on NCT00362752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362752.